Algernon Pharmaceuticals Inc. C.AGN

Chronic Cough Trials

[nodaytrader]

In response to recent comments:

1. Christopher Moreau has stated that AGN's chronic cough study will mirror the Merck and Bellus studies so that direct comparisons can be made.
2. The study will include participants in the USA - presumably the new medical board advisor can help with that.
3. Both Merck and Bellus are quoted on NASDAQ. AGN is not.
If AGN were valued on the same basis as Bellus ($1.25 billion), its share price would be over $500.

[C10H12N2]

What Christopher Moreau (CEO) says and what actually happens tends not to usually align with what one would assume. Thus, I've clearly stated the "multinational" clinical trial(s) have had the vast majority of participants located outside of North America with none/zero participants in Canada. My guess is that will be the same strategy as before. OAN: I'm also guessing